NAD+ Therapy Clinics in 2026: IV NAD+, NR, NMN, Safety, and Evidence

Short answer: no human outcomes trial has shown that IV NAD+ slows aging, extends life, prevents dementia, or improves healthspan in healthy people. Oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can change NAD-related blood markers, but clinical benefits have been inconsistent and often absent. IV delivery adds sterile-compounding and infusion risks without proven superiority for longevity outcomes.¹²

That does not make every NAD-related treatment worthless. It means the product, route, claim, evidence, and monitoring plan must be evaluated separately. A blood biomarker response is not the same as a patient benefit.

Medical note: This is buyer education, not personal medical advice or a dosing guide. Infusions and supplements can be inappropriate in some medical contexts. Discuss the exact product and your history with a qualified clinician.

Reviewed 27 August 2026: The evidence review now includes a 2026 systematic review, a July 2026 NMN meta-analysis, current FDA compounding information, and the full limitations and conflicts of the commercial IV pilot. Unverified prices, clinic endorsements, dosing recommendations, and loading protocols were removed.

What the evidence supports

The most useful 2026 synthesis reviewed 113 intervention studies, including 33 human studies and 80 rodent studies. Of the human studies, 28 were randomized. Its conclusions were much narrower than common clinic marketing:¹

• oral NR and NMN usually changed circulating or cellular NAD-related markers;
• short studies generally found them tolerable;
• functional, metabolic, vascular, and other healthspan outcomes were heterogeneous and often null;
• no eligible outcomes trial tested intravenous or intramuscular NAD+ itself for anti-aging or wellness;
• larger, longer randomized trials with clinically meaningful endpoints are still needed.

A 2025 Nature Aging review reached the same practical boundary. NAD biology is relevant to aging research, but optimal dose, route, frequency, long-term safety, and variation between people remain unresolved.²

Route or product	What human evidence can currently support	What it does not establish
Oral NR or NMN	Biochemical target engagement and short-term tolerability in studied populations	Slower aging, longer life, dementia prevention, or consistent improvements in function
IV NAD+	Direct administration into the bloodstream and limited pharmacokinetic or observational information	Better healthspan outcomes than oral precursors or placebo
IV NR	One very small commercial retrospective comparison suggests different infusion tolerability	Superior safety, effectiveness, or durable benefit
Niacin or nicotinamide	Established nutritional and medical uses in defined contexts	That a clinic’s premium NAD protocol is necessary or superior

The oral evidence is not a recommendation

The July 2026 NMN meta-analysis included 15 randomized trials lasting 14 days to 24 weeks. It did not find an increase in reported adverse events or liver-enzyme abnormalities during those short studies, but it also found no significant benefit for body weight, BMI, fasting glucose, HbA1c, lipid profiles, or systolic blood pressure. Long-term safety and efficacy remain unanswered.³

That distinction matters. “Raises NAD-related metabolites” describes a laboratory effect. “Improves how long or how well people live” describes a clinical outcome. A clinic should not use the first claim as proof of the second.

The evidence also does not justify naming one precursor, brand, dose, or schedule as the best longevity option for a general reader. Those choices depend on the actual indication, jurisdiction, product quality, medical history, and evidence available for the intended outcome.

What the IV NAD+ versus IV NR pilot really showed

The 2026 study frequently used to compare IV NAD+ with IV NR was not a randomized outcomes trial. It was a retrospective review of 14 clients in one commercial setting: six received IV NAD+ and eight received IV NR for four consecutive days, with 30 days of follow-up.⁴

The NAD+ group reported more infusion symptoms and needed longer average infusion time than the NR group. That is a tolerability signal worth studying. It is not proof that IV NR is safer or more effective.

The limitations are material:

• only 14 clients were included;
• there was no placebo or matched control group;
• follow-up lasted 30 days;
• metabolic analyses were exploratory;
• the study was funded by Restore Hyper Wellness;
• most authors were Restore Hyperwellness employees;
• the NR product was donated by Niagen Biosciences.

The paper discloses these relationships. A clinic or article should disclose them too before presenting the pilot as evidence for a commercial protocol.

FDA’s warning is about product quality, not approval

FDA reported that some compounders used food-grade NAD+ ingredients to make sterile intravenous products. Food-grade material is not automatically suitable for sterile drugs because microbes or endotoxins can harm patients. FDA also received adverse-event reports after NAD+ injectable drugs, including severe chills, shaking, vomiting, and fatigue, with some cases requiring medical treatment.⁵

This FDA communication is a safety warning. It does not approve IV NAD+ as an anti-aging or longevity treatment.

Before an infusion, ask for written answers to these questions:

1. What exact molecule and formulation will be administered?
2. Who manufactured, repackaged, or compounded it?
3. Is the ingredient suitable for sterile drug compounding rather than food or supplement use?
4. Who prescribed the infusion and what clinical problem is being addressed?
5. What dose, rate, number of sessions, and stop rules are documented?
6. Who is present during the infusion and how are reactions managed?
7. What outcome is measured, and why should that outcome matter clinically?
8. What lower-risk or better-supported alternative was considered?

If the answer is only “cellular energy” or “anti-aging,” the clinical rationale is incomplete.

What WLC directory data can and cannot prove

On 27 August 2026, 12 of the 55 clinic profiles in the local WLC data set were tagged with nadTherapy: true. That is useful for finding providers to investigate. It does not independently verify:

• whether the service is currently available;
• whether the clinic offers IV NAD+, IV NR, oral precursors, or a different product;
• the supplier, formula, dose, price, or sterile-compounding standard;
• that the treatment is legal or appropriate for a particular use;
• that the clinic’s outcome claims are supported.

Treat a directory feature as a lead, not an endorsement. Confirm current details directly and keep a dated copy of the clinic’s written answer.

How to compare cost without invented ranges

Prices vary by formulation, location, assessment, laboratory work, staff time, number of sessions, and whether the infusion is bundled into a larger program. A single global price range would be too weak to guide a purchase.

Ask for an itemized quote that separates:

• clinician assessment and contraindication review;
• product, dose, supplier, and compounding source;
• administration and expected infusion time;
• number and frequency of sessions;
• monitoring and adverse-event support;
• repeat testing and follow-up;
• cancellation or refund terms if treatment is stopped.

Compare the total planned course, not one promotional session. Higher price does not prove better evidence, and a lower price does not remove sterile-product risk.

Red flags

Pause if a clinic:

• claims IV NAD+ is proven to reverse aging or prevent dementia;
• treats a change in blood NAD-related markers as proof of clinical benefit;
• says IV delivery is superior without a relevant comparative outcomes trial;
• recommends a loading phase followed by maintenance without explaining the evidence;
• cannot identify the supplier or sterile-compounding standard;
• hides the number of participants or commercial conflicts in supporting studies;
• offers the same protocol to every client;
• has no written adverse-event and stop plan.

For a broader assessment of governance, use the clinic due-diligence checklist. If the proposed infusion is one component of a larger vitamin formula, review the separate IV nutrient therapy guide.

FAQ

Is IV NAD+ FDA-approved for longevity?

FDA’s NAD+ communication, current as of October 30, 2024, is a warning about ingredients used in sterile compounding, not an approval for anti-aging or longevity. Ask the provider for the exact product and regulatory basis of the proposed use.

Is IV NAD+ more effective than oral NR or NMN?

No comparative outcomes evidence establishes that IV NAD+ produces better longevity or healthspan results. The routes change how a product is administered, but route alone does not prove a meaningful clinical benefit.

Is IV NR safer than IV NAD+?

Not proven. One retrospective commercial pilot with 14 clients reported fewer infusion symptoms and shorter infusion times with IV NR, but it had no control group, short follow-up, industry funding, and employee authorship.⁴

Do oral NR or NMN slow aging?

Human trials show biochemical effects, but anti-aging or wellness outcomes remain inconclusive. The 2026 systematic review found healthspan-relevant results were heterogeneous and often null.¹

How long should a person use an NAD protocol?

There is no validated universal duration for longevity. A clinic should define the indication, expected outcome, reassessment date, and stop rule rather than sell indefinite maintenance by default.

Bottom line

NAD+ is a legitimate research field and an oversold commercial category at the same time. Oral precursors can change biomarkers, but consistent clinical benefits are unproven. IV NAD+ has no eligible anti-aging or wellness outcomes trials in the 2026 systematic review and introduces sterile-compounding and infusion concerns.

The buyer’s job is not to choose the most futuristic route. It is to demand a precise claim, a corresponding human outcome, a safe product source, transparent conflicts, and a stopping rule.

Footnotes

1. Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews. 2026. ↩ ↩² ↩³

2. Zhang J, et al. Emerging strategies, applications and challenges of targeting NAD+ in the clinic. Nature Aging. 2025. ↩ ↩²

3. Yang W, et al. Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults. Nutrients. 2026. ↩

4. Reyna K, et al. Intravenous infusion of NAD+ versus nicotinamide riboside: a retrospective tolerability pilot study. Frontiers in Aging. 2026. ↩ ↩²

5. U.S. Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding. Content current October 30, 2024. ↩